We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Clinical Updates

Planetary Health Diet and Cardiometabolic Risk Reduction in Women with Gestational Diabetes: An Evidence-Based Review

MedXY Editorial Team•Dec 15, 2025•Clinical Updates
cardiovascular diseaseChế độ ăn uống vì sức khỏe hành tinhGestational Diabetestype 2 diabetesweight management

Highlights

  • Higher adherence to the Planetary Health Diet (PHD) is associated with a substantially lower risk of myocardial infarction (63% reduction) among women with a history of gestational diabetes (GD).
  • Elevated PHD adherence correlates with reduced incidence of overall cardiovascular disease (CVD) and type 2 diabetes (T2D), with body mass index (BMI) playing a significant mediating role.
  • Change in diet quality, measured by the Planetary Health Diet Index (PHDI), significantly affects concurrent weight changes; decreases in PHDI align with greater weight gain during follow-up.
  • Findings emphasize the critical window postpartum for dietary interventions to mitigate long-term cardiometabolic risks in women with GD history.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Quantitative Insights into Tirzepatide and Semaglutide Using Longitudinal Systems ModelingThis study uses longitudinal modeling to compare tirzepatide and semaglutide’s effects on fasting glucose in type 2 diabetes, revealing tirzepatide’s superior control largely due to greater insulin-independent hepatic glucose production supSep 23, 2026Impact of Age at Type 1 Diabetes Onset on Mortality and Organ Complications: Insights from a Nationwide Swedish CohortYounger age at type 1 diabetes diagnosis significantly increases risks of mortality, cardiovascular, and kidney complications; each additional year delay in onset reduces these risks. This review synthesizes nationwide cohort findings and cSep 23, 2026Empagliflozin Demonstrates Uniform Cardiovascular Benefits Across Diverse Patient Subgroups in Type 2 Diabetes: Insights from the EMPRISE Real-World StudyEmpagliflozin consistently reduces major cardiovascular events, heart failure hospitalizations, and mortality across diverse sociodemographic and cardiovascular risk groups in older adults with type 2 diabetes, with especially pronounced abSep 23, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Efficacy and Safety of Semaglutide According to Frailty Status: Insights from the SELECT Randomized Clinical Trial Post Hoc Analysis
Semaglutide demonstrates consistent cardiovascular benefits and safety across frailty levels in overweight adults with cardiovascular disease, enhancing quality of life and frailty status without increased adverse events.
Sep 21, 2026
GLP-1 Receptor Agonists and the Prevention of Obstructive Sleep Apnea in Type 2 Diabetes: Insights from a Large UK Cohort StudyA comprehensive UK cohort study shows that GLP-1 receptor agonists do not reduce the incidence of obstructive sleep apnea compared to DPP-4 inhibitors in obese patients with type 2 diabetes.Sep 19, 2026
Fenofibrate Use and Reduced Risk of Sight-Threatening Diabetic Retinopathy in Type 2 Diabetes: Insights from UK Real-World DataFenofibrate use in type 2 diabetes patients is associated with a significant reduction in the risk of sight-threatening diabetic retinopathy compared to statins, based on UK primary care data over 12 years.Sep 18, 2026